Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,81 MB, PDF-dokument

  • Kathleen M. Dungan
  • Lars Bardtrum
  • Erik Christiansen
  • Johanna Eliasson
  • Linda Mellbin
  • Vincent C. Woo
  • Vilsbøll, Tina
Introduction
A post hoc analysis of the PIONEER 1–5 and 8 trials assessed the clinically relevant composite endpoints of HbA1c (glycated haemoglobin) reduction ≥ 1% and body weight loss of ≥ 5% or ≥ 10% with orally administered semaglutide versus comparators.

Methods
In the PIONEER trials, people with type 2 diabetes were randomised to orally administered semaglutide versus placebo (PIONEER 1, 4, 5 and 8), empagliflozin (PIONEER 2), sitagliptin (PIONEER 3) and liraglutide (PIONEER 4) for 26–78 weeks. This analysis assessed the proportion of people achieving an HbA1c reduction of ≥ 1% and body weight loss of ≥ 5% at week 26 and at end of treatment, and the proportion of people achieving an HbA1c reduction of ≥ 1% and body weight loss of ≥ 10% at end of treatment.

Results
Overall, 3506 people in PIONEER 1–5 and 8 were included. At week 26 and at end of treatment, odds of achieving the composite endpoint of an HbA1c reduction of ≥ 1% and body weight loss of ≥ 5% were significantly greater with orally administered semaglutide 14 mg than with placebo (PIONEER 1, 4, 5 and 8; all p < 0.0001), empagliflozin 25 mg (PIONEER 2, p < 0.0001), sitagliptin 100 mg (PIONEER 3, p < 0.0001) and liraglutide 1.8 mg (PIONEER 4, p < 0.0001). Odds of achieving the composite endpoint of HbA1c reduction of ≥ 1% and body weight loss of ≥ 10% at end of treatment were also significantly greater with orally administered semaglutide versus comparators.

Conclusion
In PIONEER 1–5 and 8, odds of achieving clinically relevant reductions in both HbA1c and body weight were significantly greater with orally administered semaglutide versus comparators.
OriginalsprogEngelsk
TidsskriftDiabetes Therapy
Vol/bind14
Udgave nummer8
Sider (fra-til)1415-1425
Antal sider11
ISSN1869-6953
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Kathleen M. Dungan reports research support from Abbott, Dexcom, Sanofi and ViaCyte; consulting fees from Boehringer Ingelheim, Dexcom and Eli Lilly; and honoraria from the Academy for Continued Healthcare Learning, Elsevier, Integritas Healthcare, Med Learning Group, Medscape and UpToDate. Lars Bardtrum and Erik Christiansen are employees and shareholders in Novo Nordisk A/S. Johanna Eliasson is an employee of Novo Nordisk A/S. Linda Mellbin reports research support from Amgen AB and Bayer AG, and lecture/consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, Novartis, Novo Nordisk and Sanofi. Vincent C. Woo has served on advisory boards, participated in clinical trials and received speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Novo Nordisk and Pfizer. Tina Vilsbøll has served on scientific advisory panels, participated in speaker bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, MSD/Merck, Mundipharma, Novo Nordisk, Sanofi and Sun Pharmaceuticals.

Funding Information:
These trials, and the journal’s Rapid Service Fee, were funded by Novo Nordisk A/S, Søborg, Denmark.

Publisher Copyright:
© 2023, The Author(s).

ID: 365702143